Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2015 Apr;59(4):2428-31. doi: 10.1128/AAC.04965-14. Epub 2015 Jan 20.

Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37.

Author information

  • 1Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA gsakoulas@ucsd.edu.
  • 2Department of Biological Sciences, University of California San Diego, La Jolla, California, USA.
  • 3College of Pharmacy, Oregon State University/Oregon Health Sciences University, Portland, Oregon, USA.
  • 4Eugene Applebaum College of Pharmacy and Health Sciences, School of Medicine, Wayne State University, Detroit, Michigan, USA.
  • 5Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA.

Abstract

Five cases of bacterial meningitis treated with ceftaroline (4 Streptococcus pneumoniae and 1 Staphylococcus aureus) are summarized here. The pharmacodynamics of human cathelicidin LL-37 and ceftaroline were evaluated against S. pneumoniae. Patients who received ceftaroline 600 mg every 8 h (q8h) (1 S. aureus and 3 S. pneumoniae) were successfully treated; treatment failed in 1 patient with S. pneumoniae who received 600 mg q12h. Ceftaroline increased the negative surface charge and sensitized S. pneumoniae to killing by LL-37, a peptide implicated in blood-brain barrier defense.

PMID:
25605351
PMCID:
PMC4356754
DOI:
10.1128/AAC.04965-14
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center